Business Description
Greenwich LifeSciences Inc
NAICS : 541714
SIC : 2834
ISIN : US3968791083
Share Class Description:
GLSI: Ordinary SharesDescription
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.86 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -54.7 | |||||
| 3-Year EPS without NRI Growth Rate | -51.1 | |||||
| 3-Year FCF Growth Rate | -60.9 | |||||
| 3-Year Book Growth Rate | -37.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.77 | |||||
| 9-Day RSI | 66.11 | |||||
| 14-Day RSI | 59.64 | |||||
| 6-1 Month Momentum % | 0.75 | |||||
| 12-1 Month Momentum % | 17.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.92 | |||||
| Quick Ratio | 6.92 | |||||
| Cash Ratio | 6.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | -2.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -166.43 | |||||
| ROA % | -151.2 | |||||
| ROIC % | -187182.61 | |||||
| ROCE % | -170.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 38.16 | |||||
| Price-to-Tangible-Book | 38.16 | |||||
| EV-to-EBIT | -17.25 | |||||
| EV-to-EBITDA | -17.26 | |||||
| EV-to-FCF | -24.53 | |||||
| Price-to-Net-Current-Asset-Value | 38.34 | |||||
| Price-to-Net-Cash | 38.34 | |||||
| Earnings Yield (Greenblatt) % | -5.8 | |||||
| FCF Yield % | -3.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLSI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Greenwich LifeSciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.8 | ||
| Beta | 1.78 | ||
| Volatility % | 101.29 | ||
| 14-Day RSI | 59.64 | ||
| 14-Day ATR ($) | 0.830129 | ||
| 20-Day SMA ($) | 13.538 | ||
| 12-1 Month Momentum % | 17.29 | ||
| 52-Week Range ($) | 8 - 21.44 | ||
| Shares Outstanding (Mil) | 13.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Greenwich LifeSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Greenwich LifeSciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Greenwich LifeSciences Inc Frequently Asked Questions
What is Greenwich LifeSciences Inc(GLSI)'s stock price today?
The current price of GLSI is $14.50. The 52 week high of GLSI is $21.44 and 52 week low is $8.00.
When is next earnings date of Greenwich LifeSciences Inc(GLSI)?
The next earnings date of Greenwich LifeSciences Inc(GLSI) is 2025-02-14 Est..
Does Greenwich LifeSciences Inc(GLSI) pay dividends? If so, how much?
Greenwich LifeSciences Inc(GLSI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers